. . . "Doxorubicin and its major metabolite, doxorubicinol, is 74-76% bound to plasma protein. The extent to binding is independent of plasma concentration up to 1.1 mcg/mL. Doxorubicin does not cross the blood brain barrier. "@en . . . . . . . . . . . . . . " "@en . . "40% of the dose appears in bile in 5 days. 5-12% of the drug and its metabolites appears in urine during the same time period. <3% of the dose recovered in urine was doxorubicinol. "@en . . . "Doxorubicine"@en . . . "* 324-809 mL/min/m2 [by metabolism and biliary excretion] * 1088 mL/min/m2 [Men] * 433 mL/min/m2 [Women] * 1540 mL/min/m2 [children greater than 2 years of age receiving administration of 10 to 75 mg/m2 doses] * 813 mL/min/m2 [infants younger than 2 years of age receiving administration of 10 to 75 mg/m2 doses]"@en . . . . . . "Doxorubicin is used to produce regression in disseminated neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms\u2019 tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, Hodgkin\u2019s disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types. Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer."@en . . "Doxorubicin"@en . . . . . . . . . "Gian P. Vicario, Sergio Penco, Federico Arcamone, \"Daunorubicin and doxorubicin labelled with .sup.14 C at the 14-position and processes for their preparation.\" U.S. Patent US4211864, issued March, 1976."@en . . . . . . "Liberal fluid intake to increase urine output and help the excretion of uric acid."@en . . . . . . . "Hydroxydaunorubicin"@en . . . . "Terminal half life = 20 - 48 hours. "@en . . . . . . . . . . . "14-hydroxydaunorubicine"@en . . . . "Doxorubicinum"@en . . . . "The distributive half-life is 5 minutes, which suggests that doxorubicin is rapidly taken up by tissue. Steady state volume of distribution = 809 to 1214 L/m2"@en . . . "14-hydroxydaunomycin"@en . . "Doxorubicin"@en . "Doxorubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action: Doxorubicin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes."@en . "Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix."@en . "Humans and other mammals"@en . . . "(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside"@en . "approved"@en . "Adriamycin"@en . . "investigational"@en . "(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione"@en . " "@en . "23214-92-8"@en . . . . . . "LD₅₀=21800 ug/kg (rat, subcutaneous)"@en . . . . . . . . . . . . . . . "# Weiss RB: The anthracyclines: will we ever find a better doxorubicin? Semin Oncol. 1992 Dec;19(6):670-86. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/1462166 # Tan C, Tasaka H, Yu KP, Murphy ML, Karnofsky DA: Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia. Cancer. 1967 Mar;20(3):333-53. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/4290058 # Arcamone F, Cassinelli G, Fantini G, Grein A, Orezzi P, Pol C, Spalla C: Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius. Biotechnol Bioeng. 1969 Nov;11(6):1101-10. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/5365804 # Di Marco A, Gaetani M, Scarpinato B: Adriamycin (NSC-123,127): a new antibiotic with antitumor activity. Cancer Chemother Rep. 1969 Feb;53(1):33-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/5772652 # Lomovskaya N, Otten SL, Doi-Katayama Y, Fonstein L, Liu XC, Takatsu T, Inventi-Solari A, Filippini S, Torti F, Colombo AL, Hutchinson CR: Doxorubicin overproduction in Streptomyces peucetius: cloning and characterization of the dnrU ketoreductase and dnrV genes and the doxA cytochrome P-450 hydroxylase gene. J Bacteriol. 1999 Jan;181(1):305-18. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9864344 # Mordente A, Meucci E, Silvestrini A, Martorana GE, Giardina B: New developments in anthracycline-induced cardiotoxicity. Curr Med Chem. 2009;16(13):1656-72. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19442138 # Minotti G: Reactions of adriamycin with microsomal iron and lipids. Free Radic Res Commun. 1989;7(3-6):143-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/2555273"@en . .